Gene Analysis
BRACAnalysis CDx®
BRACAnalysis CDx® – Confidently Recommend an Appropriate PARP Inhibitor with Fast and Accurate BRCA1/2 Results
Germline BRCA1 and BRCA2 status is a critical biomarker to help you determine the appropriate therapy for your patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer. BRACAnalysis CDx® was designed to quickly provide accurate results so you can confidently recommend the next treatment for your patient without delay.
Companion diagnostic indications
| Tumor Type | Biomarker | Therapy |
| Breast Cancer | Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes | Lynparza® (olaparib) |
| Talzenna® (talazoparib) | ||
| Ovarian Cancer | Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes | Lynparza® (olaparib)- treatment/maintenance |
| Rubraca® (rucaparib) | ||
| Pancreatic Cancer | Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes | Lynparza® (olaparib) |
| Prostate Cancer | Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes | Lynparza® (olaparib) |
For more information please call us or visit www.myriad-oncology.com
Name
BRACAnalysis CDx®
Category
Oncology
Producer
Myriad
Exclusive Distributor
